Articles related to OSTEOARTHRITIS (OA)

If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

This in-depth research opens up potential avenues for the use of ADMSCs in managing K-L grade 3 knee osteoarthritis, particularly in terms of pain and functional improvements, signifying a promising frontier in osteoarthritis treatment.

Unveiling a new path in osteoarthritis pain management, the FDA’s Breakthrough Therapy designation for resiniferatoxin marks a promising development. The FDA has granted Breakthrough Therapy designation to resiniferatoxin for treating osteoarthritis knee pain. Extracted from a cactus-like plant, resiniferatoxin, a potent TRPV1 agonist, boasts similarities to capsaicin. Notably, its potency sets it apart. Resiniferatoxin is administered through intra-articular injection, promoting pain relief by temporarily disabling TRPV1-expressing nociceptors. This unique mechanism targets one of the most profound symptoms of osteoarthritis: pain. Its potential benefits are eagerly awaited by millions of patients struggling with this relentless disease. Stepping up to the challenge, Grünenthal, the company behind resiniferatoxin, is launching a global Phase 3 program. They aim to enroll more than 1,800 patients with knee osteoarthritis who haven’t found sufficient relief from existing non-surgical treatments. With a focus on improved pain and physical function scores according to the WOMAC osteoarthritis index, the program’s efficacy endpoints are set for up to 52 weeks. Turning the tide in osteoarthritis treatment, the Breakthrough Therapy Designation offers an expedited path for this non-opioid therapy option. As Grünenthal’s Chief Scientific Officer, Jan Adams, optimistically noted, it is hoped that this designation will speed up resiniferatoxin’s availability to patients.

Jaw tightness and pain, also known as temporomandibular joint (TMJ) tightness, can be caused by various factors. Stress or anxiety can lead to muscle tension in the jaw, resulting in tightness and discomfort. TMJ disorders, teeth grinding (bruxism), tetanus infection, rheumatoid arthritis (RA), and osteoarthritis (OA) are other potential causes. To relieve a tight jaw, patients can try jaw joint stretches, opt for a soft food diet, and use mouthguards to prevent teeth grinding. Treatment options may include shortwave diathermy, hot and cold compresses, medication, or even acupuncture. It’s important for patients to consult a doctor or dentist if symptoms worsen or interfere with daily activities. By addressing the underlying cause and providing appropriate remedies, dental professionals can help patients find relief from jaw tightness and pain.

A 12-month controlled trial randomized 189 individuals to spend 70–90 minutes performing 11 exercises or 20–30 minutes performing 5 exercises for 3 months. Outcomes were measured biweekly for the intervention period and again at 6 and 12 months. The two approaches were similar, except for one outcome. In the Knee Injury and Osteoarthritis Outcome Score for function in sports and recreation, high-dose therapy was superior.